behavior/neurological
• mutants at 2 months of age exhibit a decrease in the exploration time in the activity cage, with this reduction lasting the duration of the dark cycle
|
• at 4 months of age, mutants exhibit an increased latency time to descend a pole from a fixed height, indicating poor motor coordination
• however, mutants show normal rotarod performance
• 4 month of mutants treated with L-DOPA and carbidopa, a common therapy for Parkinson Disease, exhibit improved performance on the pole test and the activity cage
|
growth/size/body
• mutants gain weight at a slower rate than controls; this slower weight gain is first observed at 2 months of age
|
homeostasis/metabolism
• mutants show a significant reduction in overall all amount of dopamine at both 4 and 12 months of age compared to controls
• mutants however show an increase in the amount of HVA and DOPA, downstream metabolites of dopamine, indicating altered dopamine metabolism in the striatum
|
• mutants over 12 months of age exhibit an increase in monoamine neurotransmitters, noradrenaline and serotonin
|
• mutants over 12 months of age exhibit an increase in monoamine neurotransmitters, noradrenaline and serotonin
|
nervous system
• at 9 months of age, but not 4 months, mutants exhibit a 60% reduction in TH+ neurons in the substantia nigra, and by 12 months of age, very few TH+ neurons are left in the substantia nigra
|
• mutants exhibit a reduction in TH+ neurons in the striatum at 4 months of age
|
• mutants exhibit a reduction in dopamine transporter steady-state levels in the striatum, indicating a reduction of dopaminergic presynaptic terminals in the striatum at 4 months of age
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
Parkinson's disease | DOID:14330 |
OMIM:PS168600 |
J:178139 |